Literature DB >> 12583851

Calcific aortic stenosis: new pathophysiologic insights and possible new medical therapy.

Lori B Croft1, Martin E Goldman.   

Abstract

Aortic stenosis is a progressive disease of aging with serious complications. A common disease of the elderly, it may inexorably progress to stenosis. Recent retrospective studies have correlated risk factors commonly associated with coronary and vascular atherosclerosis with an accelerated rate of aortic valve stenosis. Although hydroxymethyl glutaryl co-enzyme A reductase inhibitor (statin) treatment therapy has been shown to delay the rate of progression of valvular aortic stenosis, the salutary mechanism of the statin may be cholesterol-lowering and/or anti-inflammatory. Further prospective studies are warranted to investigate the mechanism and medical therapy of aortic sclerosis and stenosis.

Entities:  

Mesh:

Year:  2003        PMID: 12583851     DOI: 10.1007/s11886-003-0075-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  27 in total

Review 1.  Vascular and valvar calcification: recent advances.

Authors:  A Farzaneh-Far; D Proudfoot; C Shanahan; P L Weissberg
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

2.  Robert Butler: championing a healthy view of ageing.

Authors:  M Larkin
Journal:  Lancet       Date:  2001-01-06       Impact factor: 79.321

3.  Aortic stenosis: no more hemodynamic cardiac catheterization!

Authors:  H M Connolly; K V Ballman; V L Roger; A J Tajik
Journal:  Mayo Clin Proc       Date:  2001-09       Impact factor: 7.616

4.  Why is there discordance between calcific aortic stenosis and coronary artery disease?

Authors:  C M Otto; K D O'Brien
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

5.  Are atherosclerotic processes involved in aortic-valve calcification?

Authors:  E R Mohler
Journal:  Lancet       Date:  2000-08-12       Impact factor: 79.321

6.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

7.  Bone formation and inflammation in cardiac valves.

Authors:  E R Mohler; F Gannon; C Reynolds; R Zimmerman; M G Keane; F S Kaplan
Journal:  Circulation       Date:  2001-03-20       Impact factor: 29.690

8.  HMG CoA reductase inhibitor (statin) and aortic valve calcium.

Authors:  David M Shavelle; Junichuro Takasu; Matthew J Budoff; SongShou Mao; Xue Qiao Zhao; Kevin D O'Brien
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

9.  C-reactive protein is increased in patients with degenerative aortic valvular stenosis.

Authors:  A Galante; A Pietroiusti; M Vellini; P Piccolo; G Possati; M De Bonis; R L Grillo; C Fontana; C Favalli
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

10.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis.

Authors:  K D O'Brien; D D Reichenbach; S M Marcovina; J Kuusisto; C E Alpers; C M Otto
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-04       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.